C reactive protein levels in non-alcoholic fatty liver disease

Journal of Hepatology

Volumn 56, Issue 2, 2012, Pages 507-508

  Dogru, Teoman ^a   Genc, Halil ^a   Bagci, Sait ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH SENSITIVE C REACTIVE PROTEIN; UNCLASSIFIED DRUG;

BLOOD PRESSURE; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; FATTY LIVER; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; LETTER; LIVER BIOPSY; LIVER FIBROSIS; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; OBESITY; POPULATION; PRIORITY JOURNAL; RISK FACTOR;

BODY MASS INDEX; C-REACTIVE PROTEIN; FATTY LIVER; FEMALE; HUMANS; MALE; OBESITY;

EID: 84855975725     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.06.030     Document Type: Letter

References (10)

1. M. Yoneda High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH J Gastroenterol 42 7 2007 573 582 (Pubitemid 47190075)
2. E. Zimmermann C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients J Hepatol 55 2011 660 665
3. C. Garcia Diabetes and inflammation: fundamental aspects and clinical implications Diabetes Metab 36 5 2010 327 338
4. C. Sabanayagam Serum C-reactive protein level and prediabetes in two Asian populations Diabetologia 54 4 2011 767 775
5. J.W. Yun Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease Liver Int 29 2009 525 529
6. B.G. Nordestgaard, and J. Zacho Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr Metab Cardiovasc Dis 19 8 2009 521 524
7. G. Schillaci, and M. Pirro C-reactive protein in hypertension: clinical significance and predictive value Nutr Metab Cardiovasc Dis 16 7 2006 500 508 (Pubitemid 44472604)
8. C.E. Ndumele, and Hepatic. Steatosis Obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation Arterioscler Thromb Vasc Biol 2011 [Epub ahead of print]
9. P. Dandona Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein Mayo Clin Proc 83 3 2008 333 342 (Pubitemid 351469244)
10. P. Dandona Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade J Hum Hypertens 21 1 2007 20 27 (Pubitemid 44921816)